Journal
BONE MARROW TRANSPLANTATION
Volume 50, Issue -, Pages S67-S71Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2015.99
Keywords
-
Categories
Funding
- WIS-CSP Foundation
- Gilead
- Milteny Biotec
- Gamida cell
- Adienne Pharma and Biotech
- Medac hematology
- Kiadis Pharma
- Almog Diagnostic
Ask authors/readers for more resources
Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukemia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available